Atlas Trials

A Prevention Trial of Canakinumab in Subjects at High Risk for Lung Cancer

Clinical trial NCT05725343 · TERMINATED

Trial details

NCT number
NCT05725343
Sponsor
Mario Negri Institute for Pharmacological Research
Status
TERMINATED
Phase
Phase 3
Study type
INTERVENTIONAL
Lung Cancer
Start date
2022-02-03
Primary completion
2022-04-03
Enrollment
350

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.